Introduction {#sec1_1}
============

The pathogenesis of idiopathic thrombocytopenic purpura (ITP) is incompletely understood. Reduced platelet lifespan due to antibody-mediated destruction is the predominant hypothesis; however, other mechanisms are likely important, including autoreactive cytotoxic T cells, as well as humoral and cellular autoimmunity directed at megakaryocytes, causing impaired platelet production. The principal mechanism is thought to involve specific immunoglobulin G (IgG) autoantibodies produced by the patient\'s B cells, most often directed against platelet membrane glycoproteins such as GPIIb/IIIa \[[@B1], [@B2]\]. Many patients with ITP are asymptomatic. For those who do have symptoms, these are primarily related to thrombocytopenia and bleeding, but patients can also experience fatigue and a reduced quality of life. ITP is a diagnosis of exclusion. It is defined as isolated thrombocytopenia (platelet count \<100,000/mL) without anemia or leukopenia and without another apparent cause of the thrombocytopenia \[[@B1], [@B3]\]. The goal of ITP therapy is to provide a safe platelet count to prevent clinically important bleeding, rather than to normalize the platelet count \[[@B1], [@B3]\]. There are three principal choices of second-line treatment, which differ in their mechanism of action, efficacy, and risks: splenectomy, rituximab, and thrombopoietin receptor agonists \[[@B3], [@B4]\].

Eltrombopag is a thrombopoietin receptor agonist. The recommended daily dose is 50 mg daily to maintain a platelet count that reduces the risk of spontaneous bleeding \[[@B5]\].

The effect of obesity-related surgery on the eltrombopag function was not studied to the extent of our knowledge.

Case Report/Case Presentation {#sec1_2}
=============================

We present a case of a 46-year-old female, a known case of diabetes type 2 and hypothyroidism. The patient had sleeve gastrectomy in 2014. She presented with thrombocytopenia on 2015, and her platelet count was 37 (normal 100--400). The patient was asymptomatic. At that time, workup was done and revealed normal CBC. Her peripheral smear showed thrombocytopenia. She was not taking any medications known to cause thrombocytopenia and infection was excluded. A diagnosis of ITP was made by exclusion and the patient was started on eltrombopag 50 mg daily. One week later, her platelets increased to 100 and then to 279 in 2 weeks period. So eltrombopag was decreased to 25 mg daily and platelet count was checked after 1 week of dose reduction and found to be 182. In late 2015, the patient decided to get pregnant and she decided to stop eltrombopag after she knew that its effect on pregnancy was not well recognized. In 2019, she presented with platelet count 21 and she was asymptomatic. Again, full workup was done including complete blood count and inflammatory markers, which was normal. Medication-induced thrombocytopenia was excluded and peripheral smear showed reduced platelet number. Eltrombopag 25 mg daily was started. After 1 week, platelet count increased to 116 and 1 week later to 244. After 2 weeks of initiation of eltrombopag, the dose was reduced to 25 mg every other day and she maintain platelet count of 168 after 1 week. The patient was followed over the next few months and her platelet count is shown in Fig. [1](#F1){ref-type="fig"}

Discussion/Conclusion {#sec1_3}
=====================

The two medications commonly used as second line for ITP are rituximab and eltrombopag. Rituximab is a chimeric mouse/human monoclonal antibody that binds specifically to the transmembrane antigen CD20 \[[@B6], [@B7]\]. Eltrombopag, an oral thrombopoietin receptor agonist, is approved in the Middle East, Turkey, Asia, and Australia for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (cITP) with insufficient response to prior therapy, such as corticosteroids and immunoglobulins. To date, real-world data on eltrombopag use in patients with cITP have not been collected in a systematic manner in most countries outside the US and Europe. Eltrombopag is absorbed with a peak concentration occurring 2--6 h after oral administration. Administration of eltrombopag concomitantly with antacids, dairy products, mineral supplements, or other products containing polyvalent cations significantly reduces eltrombopag exposure. The absolute oral bioavailability of eltrombopag after administration to humans has not been established. Based on urinary excretion and metabolites eliminated in feces, the oral absorption of drug-related material following administration of a single 75-mg eltrombopag solution dose was estimated to be at least 52% \[[@B8]\]. Eltrombopag is primarily metabolized through cleavage, oxidation, and conjugation with glucuronic acid, glutathione, or cysteine \[[@B7]\]. Absorbed eltrombopag is extensively metabolized. The predominant route of eltrombopag excretion is via feces (59%) with 31% of the dose found in the urine as metabolites. Unchanged parent compound (eltrombopag olamine) is not detected in urine. Unchanged eltrombopag olamine excreted in feces accounts for approximately 20% of the dose. The plasma elimination half-life of eltrombopag is approximately 21--32 h \[[@B7]\].

For eltrombopag dose adjustment, the lowest dose should be used to achieve and maintain platelet count ≥50,000/mm^3^ as needed to reduce the risk of bleeding. It is to be discontinued if platelet count does not respond to a level that avoids clinically important bleeding after 4 weeks at the maximum of 75 mg/day \[[@B8]\].

Initial dose is 50 mg once daily (25 mg once daily for patients of Asian ethnicity, e.g., Chinese, Japanese, Korean, Taiwanese); the dose should be titrated based on platelet response. Maximum dose is 75 mg/day \[[@B8]\].

Dosage Adjustment Based on Platelet Response {#sec2_1}
--------------------------------------------

Platelet count \<50,000/mm^3^ (≥2 weeks after treatment initiation or a dose increase): increase daily dose by 25 mg (if taking 12.5 mg once daily, increase dose to 25 mg once daily prior to increasing the dose amount by 25 mg daily); maximum: 75 mg/day \[[@B8]\].

Platelet count ≥200,000/mm^3^ and ≤400,000/mm^3^ (at any time): reduce daily dose by 25 mg (if taking 25 mg once daily, decrease dose to 12.5 mg once daily); reassess in 2 weeks \[[@B8]\].

Platelet count \>400,000/mm^3^: withhold dose; assess platelet count twice weekly; when platelet count \<150,000/mm^3^, resume with the daily dose reduced by 25 mg (if taking 25 mg once daily, resume with 12.5 mg once daily) \[[@B8]\].

Platelet count \>400,000/mm^3^ after 2 weeks at the lowest dose: discontinue treatment \[[@B8]\].

So, in our case the patient started initially on 25 mg daily. Then in 2 weeks duration, her platelets increased to 244, then the dose was reduced to 12.5 mg daily and she maintained platelets, although she had sleeve gastrectomy, which will reduce availability of the drug.

Conclusion {#sec1_4}
==========

It seems that from our case, eltrombopag is not affected by sleeve gastrectomy as well as the role of ethnicity in response to thrombopoietin agonist, which should be taken into consideration; however, further studies are needed to confirm this finding.
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